RA
FURX

Royce & Associates’s FURIEX PHARMACEUTICALS INC COM STK (DE) FURX Stock Holding History

Royce & Associates’s Portfolio FURX Stock Details FURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-355,065
Closed -$30.9M – 1491
2014
Q1 		$30.9M Sell
355,065
-48,500
-12% -$3.74M 0.09% 261
2013
Q4 		$17M Buy
403,565
+170,700
+73% +$7.02M 0.05% 464
2013
Q3 		$10.2M Buy
232,865
+165,482
+246% +$6.85M 0.03% 650
2013
Q2 		$2.3M Buy
+67,383
New +$2.37M 0.01% 1027

Other funds holding FURX

D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates's FURX Position: Q2 2014 in Review

Royce & Associates sold out of FURIEX PHARMACEUTICALS INC COM STK (DE) (FURX) in Q2 2014, closing a stake of 355,065 shares — an estimated $30.9M sold.

Royce & Associates first reported a position in FURX in Q2 2013 and held it in 4 quarters. The position peaked at $30.9M in Q1 2014. 102 funds tracked by Wall St. Rank hold FURX as of Q2 2014.

  • Royce & Associates reported no remaining FURIEX PHARMACEUTICALS INC COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Royce & Associates sold 355,065 FURIEX PHARMACEUTICALS INC COM STK (DE) shares in Q2 2014, an estimated $30.9M.
  • Royce & Associates first reported a position in FURIEX PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 4 quarters.
  • Royce & Associates's FURIEX PHARMACEUTICALS INC COM STK (DE) position peaked at $30.9M in Q1 2014.
  • 102 funds tracked by Wall St. Rank held FURIEX PHARMACEUTICALS INC COM STK (DE) as of Q2 2014.

Based on Royce & Associates's 13F filing for Q2 2014, filed 11 Aug 2014.